Favezelimab, CAS 2231068-83-8

Product Description: Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902)[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Carmen Belli, et al. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies. Cancers (Basel). 2022 Sep 1;14(17):4278./[2]Gareth P. Gregory, et al. Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study.  Cancer Res (2019) 79 (13_Supplement): CT106.

CAS Number: 2231068-83-8

Molecular Weight: N/A

Compound Purity: 97.79

Research Area: Cancer

Solubility: H2O

Target: LAG-3

• Artikelnummer: MEXHY-P99613-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99613-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated